Early Infliximab Trough Levels Predict the Long-term Efficacy of Infliximab in a Randomized Controlled Trial in Patients with Active Crohn's Disease Comparing, between CT-P13 and Originator Infliximab.
Jihye ParkJae Hee CheonKang Moon LeeYoung-Ho KimByong Duk YeChang-Soo EunSung Hyun KimSun Hee LeeJoon Ho LeeStefan G SchreiberPublished in: Gut and liver (2022)
A threshold in serum infliximab trough level at week 6 and week 14 was highly predictive for long-term clinical outcomes. There were no statistical differences in serum infliximab trough levels and ADA levels between CT-P13 and originator infliximab.